Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Financial Outlook | Analyst price targets range from $14 to $15, with Skye's $59.2M cash position supporting operations through Q1 2027 despite current unprofitability |
Market Potential | With a growing obesity epidemic, Skye Bioscience targets a substantial market opportunity, competing against established players in the pharmaceutical industry |
Safety Edge | Nimacimab's peripherally restricted design aims to avoid neuropsychiatric side effects, a common issue with previous CB1 inhibitors |
Obesity Breakthrough | Skye Bioscience's nimacimab shows promise in preclinical trials, potentially revolutionizing weight management with its unique CB1 inhibitor mechanism |
Metrics to compare | SKYE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSKYEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −1.8x | −0.5x | |
PEG Ratio | 0.01 | 0.12 | 0.00 | |
Price / Book | 1.1x | 2.6x | 2.6x | |
Price / LTM Sales | - | 101.8x | 3.3x | |
Upside (Analyst Target) | - | 49.7% | 45.0% | |
Fair Value Upside | Unlock | 0.1% | 5.1% | Unlock |